Integrates gene expression with clinicopathological features
12-Gene Molecular Score, tumor size, and node status
Identify a large percentage of true low-risk patients
(6.6% average of recurrence rate)
- <70% N0 patients at low risk
- Up to 30% of N1 patients
A simple test report for clear, straightforward conversations
Identify more breast cancer patients with a true low risk of 10-year distant recurrence (Ref. Sestak) who may safely forgo chemotherapy
EndoPredict was trained and validated for women with:
- ER+, HER2- early stage breast cancer
- Surgically resected tissue
- N0 or N1 lymph status
- T1, T2, or T3 tumor status
EndoPredict is a 2nd generation breast cancer recurrence test that combines the prognostic power of a 12-Gene Molecular Score with tumor size and lymph node status.
EndoPredict provides a comprehensive assessment of the 10-year risk of distant recurrence for women with ER+, HER2- early-stage breast cancer when treated with 5-years of endocrine therapy.
EndoPredict was developed from 10-year outcomes data to offer highly precise recurrence risk
